Augmentation of therapeutic potential of curcumin using nanotechnology: current perspectives

Artificial Cells, Nanomedicine and Biotechnology

Volumn 46, Issue sup1, 2018, Pages 1004-1015

  Sivasami, Pulavendran ^a   Hemalatha, Thiagarajan ^b  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b CENTRAL LEATHER RESEARCH INSTITUTE   (India)

Author keywords

Curcumin; nanotechnology; therapeutics

Indexed keywords

BIOACTIVITY; DEGRADATION;

ACTIVE PRINCIPLES; CURCUMIN; DEGRADATION RATE; PHYSICOCHEMICAL PROPERTY; THERAPEUTIC AGENTS; THERAPEUTIC EFFICIENCY; THERAPEUTIC POTENTIALS; THERAPEUTICS;

NANOTECHNOLOGY;

ANTINEOPLASTIC AGENT; CURCUMIN; CURCUMIN DERIVATIVE; DEMETHOXYCURCUMIN; EPIGALLOCATECHIN GALLATE; FOLIC ACID; ISOPRENALINE; NANOCARRIER; NANOPARTICLE; POLYPHENOL DERIVATIVE; SILICA NANOPARTICLE; UNCLASSIFIED DRUG; DRUG CARRIER;

ANTIAPOPTOTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; GENOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; LIVER PROTECTION; MICROEMULSION; NANOEMULSION; NANOENCAPSULATION; NANOTECHNOLOGY; NEUROPROTECTION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; REVIEW; ANIMAL; CHEMISTRY; NANOMEDICINE; PROCEDURES;

ANIMALS; CURCUMIN; DRUG CARRIERS; HUMANS; NANOMEDICINE;

EID: 85054591426     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.1080/21691401.2018.1442345     Document Type: Review

References (122)

1. Goel A, Kunnumakkara AB, Aggarwal BB., Curcumin as “Curecumin: from kitchen to clinic”. Biochem Pharmacol. 2008;75:787–809
2. Hatcher H, Planalp R, Cho J, et al. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65:1631–1652
3. Manach C, Williamson G, Morand C, et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005;81:230s–242s
4. Garcea G, Jones DJL, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer. 2004;90:1011–1015
5. Pan MH, Huang TM, Lin JK., Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999;27:486–494
6. Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4:807–818
7. Sharma RA, Steward WP, Gescher AJ., Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol. 2007;595:453–470
8. Leung MHM, Kee TW., Effective stabilization of curcumin by association to plasma proteins: human serum albumin and fibrinogen. Langmuir. 2009;25:5773–5777
9. Ernest H, Shetty R., Impact of nanotechnology on biomedical sciences: review of current concepts on convergence of nanotechnology with biology. Tissue Eng. 2005;18:19
10. Bogunia-Kubik K, Sugisaka M., From molecular biology to nanotechnology and nanomedicine. Biosystems. 2002;65:123–138
11. Farokhzad OC, Langer R., Impact of nanotechnology on drug delivery. ACS Nano. 2009;3:16–20
12. Pulavendran S, Rajam M, Rose C, et al. Hepatocyte growth factor incorporated chitosan nanoparticles differentiate murine bone marrow mesenchymal stem cell into hepatocytes in vitro. IET Nanobiotechnol. 2010;4:51–60
13. Murugan R, Ramakrishna S., Nano-featured scaffolds for tissue engineering: a review of spinning methodologies. Tissue Eng. 2006;12:435–447
14. Gunasekera UA, Pankhurst QA, Douek M., Imaging applications of nanotechnology in cancer. Targ Oncol. 2009;4:169–181
15. Kumar V, Lewis SA, Mutalik S, et al. Biodegradable microspheres of curcumin for treatment of inflammation. Indian J Physiol Pharmacol. 2002;46:209–217
16. Ma Z, Shayeganpour A, Brocks DR, et al. High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomed Chromatogr. 2007;21:546–552
17. Narayanan NK, Nargi D, Randolph C, et al. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer. 2009;125:1–8
18. Rahman SMH, Telny TC, Ravi TK, et al. Role of surfactant and pH in dissolution of curcumin. Indian J Pharm Sci. 2009;71:139–142
19. Yoo SD, Lee SH, Kang E, et al. Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. Drug Dev Ind Pharm. 2000;26:27–34
20. Kaewnopparat N, Kaewnopparat S, Jangwang A, et al. Increased solubility, dissolution and physicochemical studies of curcumin-polyvinylpyrrolidone K-30 solid dispersions. World Acad Sci Eng Technol. 2009;31:229
21. Reddy PD, Swarnalatha D., Recent advances in novel drug delivery systems. Int J PharmTech Res. 2010;2:2025–2027
22. Yu H, Huang Q., Enhanced in vitro anti-cancer activity of curcumin encapsulated in hydrophobically modified starch. Food Chem. 2010;119:669–674
23. Tonnesen HH, Masson M, Loftsson T., Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm. 2002;244:127–135
24. Iwunze MO., Binding and distribution characteristics of curcumin solubilized in CTAB micelle. J Mole Liq. 2004;111:161–165
25. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64:353–356
26. Bano G, Raina RK, Zutshi U, et al. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol. 1991;41:615–617
27. Velpandian T, Jasuja R, Bhardwaj RK, et al. Piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab Pharmacokinet. 2001;26:241–247
28. Liu ZJ, Han G, Yu JG, et al. Preparation and drug releasing property of curcumin nanoparticles. Zhong Yao Cai. 2009;32:277–279
29. Li L, Braiteh FS, Kurzrock R., Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 2005;104:1322–1331
30. Lin CC, Lin HY, Chen HC, et al. Stability and characterisation of phospholipid-based curcumin-encapsulated microemulsions. Food Chem. 2009;116:923–928
31. Liu A, Lou H, Zhao L, et al. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal. 2006;40:720–727
32. Shaikh J, Ankola DD, Beniwal V, et al. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37:223–230
33. X.Wang, Y.W.Wang, Q.Huang Enhancing stability and oral bioavailability of polyphenols using nanoemulsions, in micro/nanoencapsulation of active food ingredients. Washington (DC): American Chemical Society; 2009. p. 198–212
34. Lopes-Rodrigues V, Sousa E, Vasconcelos MH., Curcumin as a modulator of p-glycoprotein in cancer: challenges and perspectives. Pharmaceuticals. 2016;9:71
35. Song IS, Cha JS, Choi MK., Characterization, in vivo and in vitro evaluation of solid dispersion of curcumin containing d-alpha-tocopheryl polyethylene glycol 1000 succinate and mannitol. Molecules. 2016;21:1386
36. Paradkar A, Ambike AA, Jadhav BK, et al. Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int J Pharm. 2004;271:281–286
37. Wang X, Jiang Y, Wang YW, et al. Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions. Food Chem. 2008;108:419–424
38. Hu L, Jia Y, Niu F, et al. Preparation and enhancement of oral bioavailability of curcumin using microemulsions vehicle. J Agric Food Chem. 2012;60:7137–7141
39. Lin CC, Lin HY, Chi MH, et al. Preparation of curcumin microemulsions with food-grade soybean oil/lecithin and their cytotoxicity on the HepG2 cell line. Food Chem. 2014;154:282–290
40. Zou L, Zheng B, Liu W, et al. Enhancing nutraceutical bioavailability using excipient emulsions: influence of lipid droplet size on solubility and bioaccessibility of powdered curcumin. J Funct Foods. 2015;15:72–83
41. Krausz AE, Adler BL, Cabral V, et al. Curcumin-encapsulated nanoparticles as innovative antimicrobial and wound healing agent. Nanomedicine. 2015;11:195–206
42. Reeves A, Vinogradov SV, Morrissey P, et al. Curcumin-encapsulating nanogels as an effective anticancer formulation for intracellular uptake. Mol Cell Pharmacol. 2015;7:25–40
43. M.Purpura, R.P.Lowery, J.M.Wilson,. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. Eur J Nutr. 2017 [Feb 16]. DOI:10.1007/s00394-016-1376-9
44. Thangapazham RL, Puri A, Tele S, et al. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol. 2008;32:1119–1123
45. Saengkrit N, Saesoo S, Srinuanchai W, et al. Influence of curcumin-loaded cationic liposome on anticancer activity for cervical cancer therapy. Colloids Surf B Biointerfaces. 2014;114:349–356
46. Dai F, Zhang X, Shen W, et al. Liposomal curcumin inhibits hypoxia-induced angiogenesis after transcatheter arterial embolization in VX2 rabbit liver tumors. Onco Targets Ther. 2015;8:2601–2611
47. Nair KL, Thulasidasan AKT, Deepa G, et al. Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination of the carrier. Int J Pharm. 2012;425:44–52
48. Tran LD, Hoang NMT, Mai TT, et al. Nanosized magnetofluorescent Fe3O4–curcumin conjugate for multimodal monitoring and drug targeting. Colloids Surf A Physicochem Eng Asp. 2010;371:104–112
49. Mancarella S, Greco V, Baldassarre F, et al. Polymer-coated magnetic nanoparticles for curcumin delivery to cancer cells. Macromol Biosci. 2015;15:1365–1374
50. Yallapu MM, Othman SF, Curtis ET, et al. Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int J Nanomedicine. 2012;7:1761–1779
51. Lv L, Shen Y, Liu J, et al. Enhancing curcumin anticancer efficacy through di-block copolymer micelle encapsulation. J Biomed Nanotechnol. 2014;10:179–193
52. Leung MHM, Colangelo H, Kee TW., Encapsulation of curcumin in cationic micelles suppresses alkaline hydrolysis. Langmuir. 2008;24:5672–5675
53. Song Z, Zhu W, Liu N, et al. Linolenic acid-modified PEG-PCL micelles for curcumin delivery. Int J Pharm. 2014;471:312–321
54. Manju S, Sreenivasan K., Hollow microcapsules built by layer by layer assembly for the encapsulation and sustained release of curcumin. Colloids Surf B Biointerfaces. 2011;82:588–593
55. Paşcalău V, Soritau O, Popa F, et al. Curcumin delivered through bovine serum albumin/polysaccharides multilayered microcapsules. J Biomater Appl. 2016;30:857–872
56. Ghosh M, Singh ATK, Xu W, et al. Curcumin nanodisks: formulation and characterization. Nanomedicine. 2011;7:162–167
57. Paramera EI, Konteles SJ, Karathanos VT., Stability and release properties of curcumin encapsulated in Saccharomyces cerevisiae, β-cyclodextrin and modified starch. Food Chem. 2011;125:913–922
58. Salaün F, Vroman I., Curcumin-loaded nanocapsules: formulation and influence of the nanoencapsulation processes variables on the physico-chemical characteristics of the particles. Int J Chem React Eng. 2009;7:11–08
59. Nam SH, Nam HY, Joo JR, et al. Curcumin-loaded PLGA nanoparticles coating onto metal stent by electrophoretic deposition techniques. Bull Korean Chem Soc. 2007;28:397
60. Tsai YM, Chien CF, Lin LC, et al. Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm. 2011;416:331–338
61. Zhao J, Liu J, Xu S, et al. Graft copolymer nanoparticles with pH and reduction dual-induced disassemblable property for enhanced intracellular curcumin release. ACS Appl Mater Interfaces. 2013;5:13216–13226
62. Patra D, Sleem F., A new method for pH triggered curcumin release by applying poly(L-lysine) mediated nanoparticle-congregation. Anal Chim Acta. 2013;795:60–68
63. Ma N, Ma C, Li C, et al. Influence of nanoparticle shape, size, and surface functionalization on cellular uptake. J Nanosci Nanotech. 2013;13:6485–6498
64. Dandekar P, Dhumal R, Jain R, et al. Toxicological evaluation of pH-sensitive nanoparticles of curcumin: acute, sub-acute and genotoxicity studies. Food Chem Toxicol. 2010;48:2073–2089
65. Li X, Yuan H, Zhang C, et al. Preparation and in-vitro/in-vivo evaluation of curcumin nanosuspension with solubility enhancement. J Pharm Pharmacol. 2016;68:980–988
66. Nirmala C, Anand S, Puvanakrishnan R., Curcumin treatment modulates collagen metabolism in isoproterenol induced myocardial necrosis in rats. Mol Cell Biochem. 1999;197:31–37
67. Nirmala C, Puvanakrishnan R., Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mole Cell Biochem. 1996;159:85–93
68. Manikandan P, Sumitra M, Aishwarya S, et al. Curcumin modulates free radical quenching in myocardial ischaemia in rats. Int J Biochem Cell Biol. 2004;36:1967–1980
69. Quiles JL, Aguilera C, Mesa MD, et al. An ethanolic-aqueous extract of Curcuma longa decreases the susceptibility of liver microsomes and mitochondria to lipid peroxidation in atherosclerotic rabbits. Biofactors. 1998;8:51–57
70. Sidhu GS, Singh AK, Thaloor D, et al. Enhancement of wound healing by curcumin in animals. Wound Repair Regen. 1998;6:167–177
71. Jacob A, Wu R, Zhou M, et al. Mechanism of the anti-inflammatory effect of curcumin: PPAR-gamma activation. PPAR Res. 2007;2007:89369
72. Jiang Y., Micro-and nano-encapsulation and controlled-release of phenolic compounds and other food ingredients. New Brunswick (NJ): Rutgers University-Graduate School-New Brunswick; 2009
73. Sou K, Inenaga S, Takeoka S, et al. Loading of curcumin into macrophages using lipid-based nanoparticles. Int J Pharm. 2008;352:287–293
74. Ramshankar YV, Suresh S, Devi K., Novel self-emulsifying formulation of curcumin with improved dissolution, antiangiogenic and anti-inflammatory activity. Clin Res Regul Aff. 2008;25:213–234
75. Sindhu K, Indra R, Rajaram A, et al. Investigations on the interaction of gold-curcumin nanoparticles with human peripheral blood lymphocytes. J Biomed Nanotechnol. 2011;7:56
76. Chaubey P, Patel RR, Mishra B., Development and optimization of curcumin-loaded mannosylated chitosan nanoparticles using response surface methodology in the treatment of visceral leishmaniasis. Expert Opin Drug Deliv. 2014;11:1163–1181
77. Maiti K, Mukherjee K, Gantait A, et al. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 2007;330:155–163
78. Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34:660–665
79. Mulik RS, Mo¨nkko¨nen J, Juvonen RO, et al. ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharmaceutics. 2010;7:815–825
80. Tiwari SK, Agarwal S, Tripathi A, et al. Bisphenol-A mediated inhibition of hippocampal neurogenesis attenuated by curcumin via canonical Wnt pathway. Mol Neurobiol. 2016;53:3010–3029
81. Liu S, Cao Y, Qu M, et al. Curcumin protects against stroke and increases levels of Notch intracellular domain. Neurol Res. 2016;38:553–559
82. Mourtas S, Canovi M, Zona C, et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1–42 peptide. Biomaterials. 2011;32:1635–1645
83. Ramalingam P, Ko YT., Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm Res. 2015;32:389–402
84. Kundu P, Das M, Tripathy K, et al. Delivery of dual drug loaded lipid-based nanoparticles across the blood–brain barrier impart enhanced neuroprotection in a rotenone-induced mouse model of Parkinson’s disease. ACS Chem Neurosci. 2016;7:1658–1670
85. Wang J, Wang Y, Liu Q, et al. Rational design of multifunctional dendritic mesoporous silica nanoparticles to load curcumin and enhance efficacy for breast cancer therapy. ACS Appl Mater Interfaces. 2016;8:26511–26523
86. Aggarwal BB, Kumar A, Bharti AC., Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363–398
87. López‐Lázaro M., Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res. 2008;52:S103–127
88. Ma Z, Haddadi A, Molavi O, et al. Micelles of poly(ethylene oxide)-b-poly(ε-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J Biomed Mater Res. 2008;86A:300–310
89. Sahu A, Kasoju N, Bora U., Fluorescence study of the curcumin-casein micelle complexation and its application as a drug nanocarrier to cancer cells. Biomacromolecules. 2008;9:2905–2912
90. Sahu A, Bora U, Kasoju N, et al. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater. 2008;4:1752–1761
91. Mukerjee A, Vishwanatha JK., Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 2009;29:3867–3875
92. Prajakta D, Ratnesh J, Chandan K, et al. Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J Biomed Nanotechnol. 2009;5:445–455
93. Yallapu MM, Maher DM, Sundram V, et al. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res. 2010;3:11
94. Rossi JJ., Receptor-targeted siRNAs. Nat Biotechnol. 2005;23:682–684
95. Ganta S, Amiji M., Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharmaceutics. 2009;6:928–939
96. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J Nanobiotechnol. 2007;5:3
97. Gupta V, Aseh A, Ríos CN, et al. Fabrication and characterization of silk fibroin-derived curcumin nanoparticles for cancer therapy. Int J Nanomedicine. 2009;4:115–122
98. Sun M, Gao Y, Guo C, et al. Enhancement of transport of curcumin to brain in mice by poly(n-butylcyanoacrylate) nanoparticle. J Nanopart Res. 2010;12:3111–3122
99. van de Luijtgaarden W, Guha S, Milano F, et al. Nano-curcumin as a promising new therapy for treatment of esophageal adenocarcinoma. Gastroenterology. 2011;140:S–223–S-224
100. Klippstein R, Wang JTW, El-Gogary RI, et al. Passively targeted curcumin-loaded PEGylated PLGA nanocapsules for colon cancer therapy in vivo. Small. 2015;11:4704–4722
101. Anitha A, Sreeranganathan M, Chennazhi KP, et al. In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N,O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies. Eur J Pharm Biopharm. 2014;88:238–251
102. Popat A, Karmakar S, Jambhrunkar S, et al. Curcumin-cyclodextrin encapsulated chitosan nanoconjugates with enhanced solubility and cell cytotoxicity. Colloids Surf B Biointerfaces. 2014;117:520–527
103. Rao W, Zhang W, Poventud-Fuentes I, et al. Thermally responsive nanoparticle-encapsulated curcumin and its combination with mild hyperthermia for enhanced cancer cell destruction. Acta Biomater. 2014;10:831–842
104. Tima S, Okonogi S, Ampasavate C, et al. Development and characterization of FLT3-specific curcumin-loaded polymeric micelles as a drug delivery system for treating FLT3-overexpressing leukemic cells. J Pharm Sci. 2016;105:3645–3657
105. Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol. 2008;76:1590–1611
106. Markatou E, Gionis V, Chryssikos GD, et al. Molecular interactions between dimethoxycurcumin and Pamam dendrimer carriers. Int J Pharm. 2007;339:231–236
107. Basile V, Ferrari E, Lazzari S, et al. Curcumin derivatives: molecular basis of their anti-cancer activity. Biochem Pharmacol. 2009;78:1305–1315
108. Adams BK, Ferstl EM, Davis MC, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem. 2004;12:3871–3883
109. Furness MS, Robinson TP, Ehlers T, et al. Antiangiogenic agents: studies on fumagillin and curcumin analogs. Curr Pharm Des. 2005;11:357–373
110. Ohori H, Yamakoshi H, Tomizawa M, et al. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther. 2006;5:2563–2571
111. Anuradha C, Aukunuru J., Preparation, characterisation and in vivo evaluation of bis-demethoxy curcumin analogue (BDMCA) nanoparticles. Trop J Pharm Res. 2010;9:51–58
112. Subramanian SB, Francis AP, Devasena T., Chitosan-starch nanocomposite particles as a drug carrier for the delivery of bis-desmethoxy curcumin analog. Carbohydr Polym. 2014;114:170–178
113. Kesharwani P, Banerjee S, Padhye S, et al. Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancer. Colloids Surf B Biointerfaces. 2015;132:138–145
114. Qiu C, Hu Y, Wu K, et al. Synthesis and biological evaluation of allylated mono-carbonyl analogues of curcumin (MACs) as anti-cancer agents for cholangiocarcinoma. Bioorg Med Chem Lett. 2016;26:5971–5976
115. Misra R, Sahoo SK., Coformulation of doxorubicin and curcumin in poly(d,l-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharmaceutics. 2011;8:852–866
116. Duan J, Mansour HM, Zhang Y, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm. 2012;426:193–201
117. Zhao X, Chen Q, Li Y, et al. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice. Eur J Pharm Biopharm. 2015;93:27–36
118. Jiao Y, Wilkinson J, Christine Pietsch E, et al. Iron chelation in the biological activity of curcumin. Free Radic Biol Med. 2006;40:1152–1160
119. Jiao Y, Wilkinson J, Di X, et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood. 2008;113:462–469
120. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895–2900
121. Burgos-Moron, E, Calderón-Montaño JM, Salvador J, et al. The dark side of curcumin. Int J Cancer. 2010;126(7):1771–1775
122. Canamares MV, Garcia-Ramos JV, Sanchez-Cortes S., Degradation of curcumin dye in aqueous solution and on ag nanoparticles studied by ultraviolet-visible absorption and surface-enhanced Raman spectroscopy. Appl Spectrosc. 2006;60:1386–1391